The CHOIR trial also revealed increased risk or significantly greater hazard in patients with the higher hemoglobin target that was not seen in patients with diabetes or heart failure, indicating that comorbidities differentially affect outcomes in EPO treatment of anemia [196]. Here, EPO is linked to diabetes mellitus.